Summary by Moomoo AI
Medtronic reported Q2 fiscal 2024 revenue of $7.98 billion, up 5% year-over-year, with growth across all major segments. Net income rose to $909 million or $0.68 per share, compared to $427 million or $0.32 per share in the prior year. The effective tax rate decreased to 30.6% from 68.7% last year.The Cardiovascular segment grew 6% to $2.92 billion, led by strong performance in Micra, TAVR and Perfusion products. Neuroscience revenue increased 5% to $2.29 billion driven by Core Spine and Neurosurgery growth, while Medical Surgical rose 7% to $2.14 billion on strength in Advanced Surgical Technologies. Diabetes revenue grew 10% to $610 million, benefiting from the U.S. launch of the MiniMed 780G insulin pump system.The company maintained a strong financial position with $1.31 billion in cash and $6.42 billion in investments. Operating cash flow was $1.54 billion for the first half. Looking ahead, Medtronic faces potential headwinds from competitive pressures, pricing challenges, and geopolitical uncertainties but remains focused on innovation and market expansion across its portfolio.